| Gene ID | 1559 |
| Symbol | CYP2C9 |
| Synonymous | CPC9|CYP2C|CYP2C10|CYPIIC9|P450IIC9 |
| Full name | cytochrome P450, family 2, subfamily C, polypeptide 9 |
| Gene description | cytochrome P-450 S-mephenytoin 4-hydroxylase|cytochrome P-450MP|cytochrome P450 2C9|cytochrome P450 PB-1|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase |
| Cytoband | 10q24 |
| Gene type | protein-coding |
| Synonymous | MIM:601130; HGNC:HGNC:2623; Ensembl:ENSG00000138109; HPRD:03084; Vega:OTTHUMG00000018805 |
Pathways and Diseases | Detail |
|---|---|
Pathway | Xenobiotics;PID Reactome;500197 |
Pathway | Metabolism of xenobiotics by cytochrome P450;KEGG PATHWAY;hsa00980 |
Pathway | Metabolic pathways;KEGG PATHWAY;hsa01100 |
Pathway | Biological oxidations;Reactome;REACT:13433 |
Pathway | Linoleic acid metabolism;KEGG PATHWAY;hsa00591 |
Pathway | Drug metabolism - cytochrome P450;KEGG PATHWAY;hsa00982 |
Pathway | Retinol metabolism;KEGG PATHWAY;hsa00830 |
Pathway | Arachidonic acid metabolism;KEGG PATHWAY;hsa00590 |
Disease | warfarin response;GAD |
Disease | hyperlipidemia;GAD |
Disease | lornoxicam pharmacokinetics;GAD |
Disease | flubiprofen metabolism;GAD |
Disease | HEMATOLOGICAL;GAD |
Disease | warfarin maintenance dose;GAD |
Disease | indisulam pharmacokinetics;GAD |
Disease | coumarin sensitivity;GAD |
Disease | Warfarin sensitivity;OMIM |
Disease | glibenclamide pharmacokinetics lornoxicam pharmacokinetics;GAD |
Disease | phenytoin metabolism;GAD |
Disease | coagulation disorder;GAD |
Disease | anticoagulant complications;GAD |
Disease | risperidone metabolism;GAD |
Disease | hypertension;GAD |
Disease | bleeding events, warfarin therapy-related;GAD |
Disease | glucose;GAD |
Disease | depression;GAD |
Disease | insulin secretion;GAD |
Disease | PHARMACOGENOMIC;GAD |
Disease | METABOLIC;GAD |
Disease | depressive disorder, major;GAD |
Disease | hypoglycemia;GAD |
Disease | rosuvastatin pharmacokinetics;GAD |
Disease | blood and blood forming organ disorders;GAD |
Disease | clopidogrel;GAD |
Disease | overanticoagulation, warfarin therapy-related;GAD |
Disease | warfarin sensitivity;GAD |
Disease | PSYCH;GAD |
Disease | Tolbutamide poor metabolizer;OMIM |
Disease | chlorpropamide pharmacokinetics;GAD |
Disease | irbesartan phamacokinetics;GAD |
Disease | CARDIOVASCULAR;GAD |
Disease | acenocoumarol pharmacokinetics;GAD |
Disease | CANCER;GAD |
Disease | gastrointestinal bleeding;GAD |
Disease | phenytoin levels;GAD |
Disease | epilepsy;GAD |
Disease | phenytoin;GAD |
Disease | warfarin therapy, response to;GAD |
Disease | bleeding complications;GAD |
Disease | NEUROLOGICAL;GAD |
Disease | Warfarin maintenance dose;NHGRI |
Disease | warfarin therapy;GAD |
Disease | heart rate;GAD |
Disease | losartan oxidation;GAD |
Disease | acenocoumarol response;GAD |
Disease | colorectal cancer;GAD |
Disease | myocardial infarct;GAD |
Disease | over anticoagulation;GAD |
Disease | phenprocoumon requirements;GAD |
Sequence Information | |
|---|---|
Nucleotide Sequence | >1559 : length: 1876 GTCTTAACAAGAAGAGAAGGCTTCAATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGGAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGG CCCCACTCCTCTCCCAGTGATTGGAAATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTCTATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAA ACCCATAGTGGTGCTGCATGGATATGAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTCCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAAT TGTTTTCAGCAATGGAAAGAAATGGAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGCATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCT TGTGGAGGAGTTGAGAAAAACCAAGGCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCCATTATTTTCCATAAACGTTTTGATTATAAAGATCA GCAATTTCTTAACTTAATGGAAAAGTTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCTCCTATCATTGATTACTTCCCGGGAACTCACAACAA ATTACTTAAAAACGTTGCTTTTATGAAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCTCAGGACTTTATTGATTGCTTCCTGATGAAAATGGA GAAGGAAAAGCACAACCAACCATCTGAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAGACGACAAGCACAACCCTGAGATATGCTCTCCTTCT CCTGCTGAAGCACCCAGAGGTCACAGCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAAGACAGGAGCCACATGCCCTACACAGATGCTGTGGT GCACGAGGTCCAGAGATACATTGACCTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTCATTCCCAAGGGCACAACCATATTAATTTCCCTGAC TTCTGTGCTACATGACAACAAAGAATTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAGAAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAA ACGGATTTGTGTGGGAGAAGCCCTGGCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCTCTGGTTGACCCAAAGAACCTTGACACCACTCCAGT TGTCAATGGATTTGCCTCTGTGCCGCCCTTCTACCAGCTGTGCTTCATTCCTGTCTGAAGAAGAGCAGATGGCCTGGCTGCTGCTGTGCAGTCCCTGCAGCTCTCTTTCCTCTGGGGCAT TATCCATCTTTCACTATCTGTAATGCCTTTTCTCACCTGTCATCTCACATTTTCCCTTCCCTGAAGATCTAGTGAACATTCGACCTCCATTACGGAGAGTTTCCTATGTTTCACTGTGCA AATATATCTGCTATTCTCCATACTCTGTAACAGTTGCATTGACTGTCACATAATGCTCATACTTATCTAATGTTGAGTTATTAATATGTTATTATTAAATAGAGAAATATGATTTGTGTA TTATAATTCAAAGGCATTTCTTTTCTGCATGTTCTAAATAAAAAGCATTATTATTTGCTGAAAAAAAAAAAAAAAA |
Protein Sequence | >1559 : length: 490 MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP PFYQLCFIPV |